Akili Secures $160 Million in Financing; Poised to Deliver on the Promise of Digital Therapeutics
Funding will accelerate commercialization of Akili’s flagship treatment EndeavorRxTM, enable expansion of Akili’s core technology to treat acute and chronic cognitive disorders, and drive further research and development of new technologies to treat broader range of conditions
BOSTON, Mass. – May 26, 2021 – Akili Interactive (“Akili” or “Company”), maker of EndeavorRxTM, the first and only prescription video game treatment, today announced $160M in combined equity and debt financing. Akili is a pioneer of a new class of medicine and treatments that are not only effective and clinically-validated but that deliver amazing experiences to patients. The Company’s flagship product made history in June 2020 when it received U.S. Food and Drug Administration (FDA) clearance. With the completion of the oversubscribed Series D financing, Akili will continue to push the boundaries of traditional medicine to deliver on the promise of digital therapeutics for patients.
The $110M Series D equity financing was led by Neuberger Berman Funds and joined by new investors Polaris Partners; Mirae Assets; Shionogi & Co., Ltd., New Leaf Venture Partners; Dave Baszucki, Founder and CEO of Roblox Corporation; QUAD Investment Management, and Ladera Venture Partners. Existing Akili investors Temasek, Baillie Gifford, JAZZ Venture Partners, Evidity Health Capital, Omidyar Technology Ventures, Fearless Ventures, Amgen Ventures, and M Ventures (the corporate VC fund of Merck KGaA, Darmstadt, Germany) all participated in the financing round.
This funding will support a go-to market approach that brings EndeavorRx to families and healthcare professionals at scale and expand Akili’s global footprint within attention- deficit/hyperactivity disorder (ADHD) and beyond. The financing will also enable Akili to build on the success of its patented technology platform, which has shown positive results in clinical trials across a number of indications, and further advance its pipeline of prescription digital therapeutics (PDTs) targeting a range of chronic and acute cognitive disorders. By investing in these priorities, Akili is continuing to reimagine treatment options for the hundreds of millions of people living with cognitive impairments.